DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,803,545 | -30.1% | 378,262 | -0.0% | 0.74% | -13.8% |
| Q2 2023 | $11,162,659 | +66.9% | 378,267 | +30.3% | 0.86% | +51.9% |
| Q1 2023 | $6,689,203 | +92203.1% | 290,330 | +11.4% | 0.57% | -13.0% |
| Q4 2022 | $7,247 | -99.9% | 260,604 | 0.0% | 0.65% | -18.4% |
| Q3 2022 | $7,998,000 | +853.3% | 260,604 | +813.8% | 0.80% | +852.4% |
| Q2 2022 | $839,000 | -28.8% | 28,519 | +7.8% | 0.08% | -9.7% |
| Q1 2022 | $1,179,000 | 0.0% | 26,445 | 0.0% | 0.09% | 0.0% |
| Q4 2021 | $1,179,000 | +84.2% | 26,445 | +108.3% | 0.09% | +63.2% |
| Q3 2021 | $640,000 | +97.5% | 12,695 | +207.2% | 0.06% | +96.6% |
| Q2 2021 | $324,000 | – | 4,133 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |